InterCure Inkomsten in het verleden

Verleden criteriumcontroles 0/6

InterCure has been growing earnings at an average annual rate of 1%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 45.1% per year.

Belangrijke informatie

1.0%

Groei van de winst

10.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie35.1%
Inkomstengroei45.1%
Rendement op eigen vermogen-14.6%
Nettomarge-24.1%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably Well

Feb 16
These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably Well

What InterCure Ltd.'s (TLV:INCR) P/E Is Not Telling You

Sep 19
What InterCure Ltd.'s (TLV:INCR) P/E Is Not Telling You

Here's Why InterCure (TLV:INCR) Can Manage Its Debt Responsibly

Aug 22
Here's Why InterCure (TLV:INCR) Can Manage Its Debt Responsibly

InterCure (TLV:INCR) Seems To Use Debt Quite Sensibly

Feb 14
InterCure (TLV:INCR) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably Well

Sep 11
These 4 Measures Indicate That InterCure (TLV:INCR) Is Using Debt Reasonably Well

What Percentage Of InterCure Ltd (TLV:INCR) Shares Do Insiders Own?

Mar 08
What Percentage Of InterCure Ltd (TLV:INCR) Shares Do Insiders Own?

Shareholders Are Raving About How The InterCure (TLV:INCR) Share Price Increased 936%

Jan 12
Shareholders Are Raving About How The InterCure (TLV:INCR) Share Price Increased 936%

Is InterCure (TLV:INCR) Using Debt Sensibly?

Dec 04
Is InterCure (TLV:INCR) Using Debt Sensibly?

Opbrengsten en kosten

Hoe InterCure geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

TASE:INCR Opbrengsten, kosten en inkomsten (ILS Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24273-66930
31 Mar 24312-61960
31 Dec 23356-62980
30 Sep 23388-201030
30 Jun 23415211101
31 Mar 23408321091
31 Dec 22389451021
30 Sep 2236333961
30 Jun 2232424801
31 Mar 2227415671
31 Dec 212205571
30 Sep 2116717431
30 Jun 2112820352
31 Mar 219413302
31 Dec 2065-37272
30 Sep 2040-63262
30 Jun 2020-80322
31 Mar 2011-91412
31 Dec 199-6832
30 Sep 1977811
30 Jun 19518720
31 Mar 19227580
31 Dec 180-13100
30 Sep 180-1050
30 Jun 180-810
31 Mar 180-710
31 Dec 170-610
30 Sep 170-410
30 Jun 170-210
31 Mar 170-210
31 Dec 160010
30 Sep 160020
30 Jun 160-120
31 Mar 161020
31 Dec 151-220
30 Sep 152-130
30 Jun 153-230
31 Mar 154-440
31 Dec 146-460
30 Sep 147-560
30 Jun 147-560
31 Mar 148-670
31 Dec 138-780

Kwaliteitswinsten: INCR is currently unprofitable.

Groeiende winstmarge: INCR is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: INCR is unprofitable, but has reduced losses over the past 5 years at a rate of 1% per year.

Versnelling van de groei: Unable to compare INCR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: INCR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).


Rendement op eigen vermogen

Hoge ROE: INCR has a negative Return on Equity (-14.58%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden